56,885 Shares in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Bought by State of New Jersey Common Pension Fund D

State of New Jersey Common Pension Fund D bought a new stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 56,885 shares of the specialty pharmaceutical company's stock, valued at approximately $1,774,000. State of New Jersey Common Pension Fund D owned about 0.10% of Supernus Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in SUPN. Meritage Portfolio Management lifted its holdings in Supernus Pharmaceuticals by 10.8% during the 3rd quarter. Meritage Portfolio Management now owns 44,295 shares of the specialty pharmaceutical company's stock worth $1,381,000 after buying an additional 4,328 shares in the last quarter. Assetmark Inc. raised its stake in shares of Supernus Pharmaceuticals by 2.8% in the third quarter. Assetmark Inc. now owns 33,442 shares of the specialty pharmaceutical company's stock valued at $1,043,000 after acquiring an additional 908 shares in the last quarter. Principal Financial Group Inc. boosted its holdings in Supernus Pharmaceuticals by 5.4% in the third quarter. Principal Financial Group Inc. now owns 285,411 shares of the specialty pharmaceutical company's stock valued at $8,899,000 after purchasing an additional 14,566 shares during the period. QRG Capital Management Inc. grew its stake in Supernus Pharmaceuticals by 6.2% during the 3rd quarter. QRG Capital Management Inc. now owns 16,801 shares of the specialty pharmaceutical company's stock worth $524,000 after purchasing an additional 986 shares in the last quarter. Finally, James Investment Research Inc. increased its holdings in Supernus Pharmaceuticals by 39.8% during the 3rd quarter. James Investment Research Inc. now owns 17,644 shares of the specialty pharmaceutical company's stock worth $550,000 after purchasing an additional 5,022 shares during the period.

Insider Buying and Selling at Supernus Pharmaceuticals

In other Supernus Pharmaceuticals news, SVP Frank Mottola sold 15,000 shares of the company's stock in a transaction that occurred on Thursday, November 7th. The stock was sold at an average price of $36.98, for a total transaction of $554,700.00. Following the completion of the sale, the senior vice president now directly owns 8,200 shares of the company's stock, valued at $303,236. This represents a 64.66 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Jack A. Khattar sold 125,000 shares of the stock in a transaction on Thursday, November 7th. The stock was sold at an average price of $36.68, for a total value of $4,585,000.00. Following the sale, the chief executive officer now directly owns 926,172 shares of the company's stock, valued at approximately $33,971,988.96. This represents a 11.89 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 154,213 shares of company stock worth $5,660,180. 9.30% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

SUPN has been the topic of a number of recent analyst reports. Cowen reissued a "buy" rating on shares of Supernus Pharmaceuticals in a research report on Friday, October 18th. Piper Sandler reaffirmed a "neutral" rating on shares of Supernus Pharmaceuticals in a report on Friday, October 18th. Finally, StockNews.com raised Supernus Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Wednesday, August 7th.

Supernus Pharmaceuticals Price Performance

Shares of SUPN traded up $0.08 during midday trading on Tuesday, reaching $35.33. 78,779 shares of the stock were exchanged, compared to its average volume of 448,265. The company has a market capitalization of $1.95 billion, a price-to-earnings ratio of 32.94 and a beta of 0.86. Supernus Pharmaceuticals, Inc. has a twelve month low of $25.53 and a twelve month high of $39.37. The business's 50-day moving average price is $33.38 and its 200 day moving average price is $30.96.

Supernus Pharmaceuticals (NASDAQ:SUPN - Get Free Report) last announced its earnings results on Monday, November 4th. The specialty pharmaceutical company reported $0.69 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.44 by $0.25. Supernus Pharmaceuticals had a net margin of 9.16% and a return on equity of 7.79%. The business had revenue of $175.70 million for the quarter, compared to analyst estimates of $157.35 million. During the same period last year, the firm posted ($0.29) earnings per share. The company's revenue for the quarter was up 14.2% compared to the same quarter last year. As a group, equities research analysts expect that Supernus Pharmaceuticals, Inc. will post 2.37 earnings per share for the current fiscal year.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.